Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

psoriasis 14, pustular - Clinical Profile, Genes & Research | Kisho | Kisho

Features include always present findings: Parakeratosis, Epidermal acanthosis, Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration), and Increased total neutrophil count and others; and sometimes findings: Geographic tongue, Polyarticular arthritis, Furrowed tongue, and Oligoarthritis and others. 15 total HPO annotations.

Organ System	Phenotype Count	Example Features
Skin	3	Erythema, Nail dystrophy, Psoriasiform dermatitis
Blood and immune system	2	Increased total neutrophil count, Elevated white blood cell count (increased total leukocyte count)
Bones and joints	1	Polyarticular arthritis
Lab test results	1	Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration)
Metabolism	1	Fever

Age of onset: adulthood.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for psoriasis 14, pustular. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for psoriasis 14, pustular, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for psoriasis 14, pustular. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Spevigo	spesolimab-sbzo	Boehringer Ingelheim Pharmaceuticals, Inc. (BI)	2018	2031	Designated (drug approved for other indication)

Gene therapy approaches for psoriasis 14, pustular have been reported in the published literature.

Clinical Trials

20 trials found

Explore Trials

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

20 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE4, 4 PHASE3, 5 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06100991](https://clinicaltrials.gov/study/NCT06100991)	CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry	—	CorEvitas	RECRUITING
[NCT06477536](https://clinicaltrials.gov/study/NCT06477536)	Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis	PHASE2	Shanghai Huaota Biopharmaceutical Co., Ltd.	RECRUITING
[NCT07013201](https://clinicaltrials.gov/study/NCT07013201)	A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis	PHASE2	LEO Pharma	RECRUITING
[NCT07270003](https://clinicaltrials.gov/study/NCT07270003)	A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis	NA	Xijing Hospital	RECRUITING
[NCT05994976](https://clinicaltrials.gov/study/NCT05994976)	Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers	—	Innovaderm Research Inc.	RECRUITING

202 publications have been identified in PubMed for psoriasis 14, pustular. Research spans Epidemiology / Natural History (20%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).

Research Type	Count	% of Total
Disease patterns and progression	41	20%
Research summaries	40	20%
Patient case studies	40	20%
Clinical study results	38	19%
Laboratory research	20	10%
Other research	12

Recent Publications

Takahashi Y (2026). [PMID: 41670195](https://pubmed.ncbi.nlm.nih.gov/41670195/). *J Dermatol*. [Epidemiology / Natural History]
Cravo JM (2026). [PMID: 41489172](https://pubmed.ncbi.nlm.nih.gov/41489172/). *J Dermatol*. [Case Report / Case Series]
Gleeson D (2026). [PMID: 40452648](https://pubmed.ncbi.nlm.nih.gov/40452648/). *Journal of the European Academy of Dermatology and Venereology : JEADV*. [Review / Meta-Analysis]
Lee H (2026). [PMID: 41740929](https://pubmed.ncbi.nlm.nih.gov/41740929/). *J Allergy Clin Immunol*. [Basic Science / Preclinical]
Mori Y (2026). [PMID: 41845909](https://pubmed.ncbi.nlm.nih.gov/41845909/). *J Dermatol*. [Other]
Delmotte A (2026). [PMID: 41713591](https://pubmed.ncbi.nlm.nih.gov/41713591/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Zheng YX (2026). [PMID: 41061969](https://pubmed.ncbi.nlm.nih.gov/41061969/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Mai SZ (2026). [PMID: 41549598](https://pubmed.ncbi.nlm.nih.gov/41549598/). *J Dtsch Dermatol Ges*. [Case Report / Case Series]
Kishimoto M (2026). [PMID: 42076875](https://pubmed.ncbi.nlm.nih.gov/42076875/). *J Dermatol*. [Basic Science / Preclinical]
Tao Y (2026). [PMID: 42183095](https://pubmed.ncbi.nlm.nih.gov/42183095/). *JAAD Case Rep*. [Case Report / Case Series]

Kisho

psoriasis 14, pustular

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Treatment

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Behçet's-Like Syndrome Associated With Psoriasis, Lichen Sclerosus and Variant in NF-κB1.

Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Oruka surges as long-acting psoriasis drug shows early promise

psoriasis 14, pustular

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Treatment

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Behçet's-Like Syndrome Associated With Psoriasis, Lichen Sclerosus and Variant in NF-κB1.

Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Oruka surges as long-acting psoriasis drug shows early promise